Fidelity Investments’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Fidelity Investments’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-674,047	Closed	-$2.04M	–	5583
2023 Q2	$2.04M	Sell	674,047 -972,342	-59%	-$3.75M	﹤0.01%	2306
2023 Q1	$10.3M	Sell	1,646,389 -441,888	-21%	-$2.69M	﹤0.01%	1864
2022 Q4	$12.7M	Sell	2,088,277 -341,825	-14%	-$2.78M	﹤0.01%	1804
2022 Q3	$29M	Buy	2,430,102 +236,786	+11%	+$3.1M	﹤0.01%	1475
2022 Q2	$27.7M	Buy	2,193,316 +749,012	+52%	+$6.97M	﹤0.01%	1523
2022 Q1	$16.3M	Sell	1,444,304 -648,219	-31%	-$7.14M	﹤0.01%	1884
2021 Q4	$37.1M	Sell	2,092,523 -4,823	-0.2%	-$102K	﹤0.01%	1547
2021 Q3	$48.3M	Sell	2,097,346 -7,675	-0.4%	-$167K	﹤0.01%	1425
2021 Q2	$49M	Sell	2,105,021 -26,627	-1%	-$677K	﹤0.01%	1440
2021 Q1	$65.1M	Sell	2,131,648 -318,487	-13%	-$11.1M	0.01%	1268
2020 Q4	$94.1M	Buy	+2,450,135	New	+$98.3M	0.01%	1058

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments's KNTE Position: Q3 2023 in Review

Fidelity Investments sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 674,047 shares — an estimated $2.04M sold.

Fidelity Investments first reported a position in KNTE in Q4 2020 and held it in 11 quarters. The position peaked at $94.1M in Q4 2020. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

Fidelity Investments reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Fidelity Investments sold 674,047 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $2.04M.
Fidelity Investments first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Fidelity Investments's Kinnate Biopharma Inc. Common Stock position peaked at $94.1M in Q4 2020.
58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on Fidelity Investments's 13F filing for Q3 2023, filed 13 Nov 2023.